Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Grifols Therapeutics LLC
EIR
•Grifols Therapeutics LLC•December 13, 2018

Grifols Therapeutics LLC – FDA EIR, Dec 13, 2018

Record Details

An FDA inspection of Grifols Therapeutics LLC in Clayton, NC, was conducted from December 4-13, 2018, under the Team Biologics program, adhering to Compliance Program CP 7345.848 for biological drug products manufactured under License #1871. The inspection revealed critical compliance issues. Primarily, there was a failure to thoroughly investigate unexplained discrepancies, particularly concerning adverse event trends for Gamunex-C lots. Pharmacovigilance requests for lot investigations were not adequately communicated or classified, leading to insufficient root cause analyses even after two Gamunex lots were recalled due to unexpected hypersensitivity reactions. The investigations performed were limited to batch record reviews, without additional analytical or source material assessment. Secondly, seven out of seven reviewed requalification training records for personnel performing visual inspection of filled products showed failing test results. These failures were not identified, resulting in no remedial training or product impact assessments, indicating inadequate visual inspection and training systems. Other observations included deficiencies in aseptic processing environmental monitoring systems, incomplete smoke studies for filling lines, and inadequate quality review processes for media fill records and environmental monitoring. At the inspection's conclusion, an FDA-483 was issued. Grifols management committed to expanded characterization testing for recalled lots, providing samples to the FDA, and conducting more thorough root cause investigations to address the identified quality and training system deficiencies.

Company
Grifols Therapeutics LLC
Inspection date
December 13, 2018
Product type
biologics
Office
Center for Biologics Evaluation and Research
Person
  • Cynthia Jim
View Company Profile

ID · 32fb0695-4a70-4b07-8eb5-312e0f5fbac0

Violation Codes1
21 CFR 820.198

Full citation text and observation details available on the Dashboard.

Other documents for Grifols Therapeutics LLC
  • 483 - 2026-02-05February 5, 2026
  • 483 - 2023-09-01September 1, 2023
  • 483 - 2022-05-06May 6, 2022
  • EIR - 2022-05-06May 6, 2022
  • 483 - 2018-12-13December 13, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Grifols Therapeutics LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.